Posaconazole (POS) Compared to Amphotericin B Lipid Formulations (AmB/LPD) alone or in Combination with Itraconazole (IT) as Salvage Therapy for Invasive Aspergillosis (IA) in Patients (pts) with Hematologic Malignancy (HM)

ISSAM I. RAAD, MD, MAHA R. BOKTOUR, MD, HEND A. HANNA, MD, DIMITRIOS P. KONTOYIANNIS, MD, RAY Y. HACHEM, MD;

Author address: 

University of Texas, M.D. Anderson Cancer Center, Houston, TX.

Abstract: 

Background: In an open trial POS was shown to be effective as salvage therapy of IA with approximately 40% response rate. Comparisons with AmB/LPD given as salvage alone or in combination with IT have not been performed. We sought to compare POS to AmB/LPD alone or with IT as salvage therapy of IA in HM. Methods: Between June 1993 and June 2003, 48 pts with HM and definite or probable IA (according to EORTC/MSG criteria) received salvage therapy with POS while 39 similar pts received AmB/LPD alone or AmB/LPD plus IT (25 Pts). Clinical characteristics, including age, gender, underlying malignancy, neutropenia, transplantation, ICU status, steroid or tacrolimus use, Aspergillus species, site of infection, and response to salvage therapy, were retrospectively obtained. Results: Pts in the three groups had comparable risk factors such as age, underlying malignancy, persistence of neutropenia, steroid and tacrolimus use, BMT, GVHD, Aspergillus species and disseminated IA. However, pts in the POS group were less frequently on mechanical ventilation (13% for POS vs. 46% for AmB/LPD and 36% for AmB/LPD plus IT P
2004

abstract No: 

NULL

Full conference title: 

42nd Annual Meeting Infectious Diseases Society of America
    • Infectious Diseases Society of America 42nd